Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.
$OCUL
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 6/20/2024 | $7.00 → $11.00 | Hold → Buy | TD Cowen |
| 5/31/2024 | $15.00 | Overweight | Piper Sandler |
| 2/9/2024 | $15.00 | Buy | BofA Securities |
| 4/21/2023 | $18.00 | Outperform | Robert W. Baird |
| 8/10/2022 | $15.00 | Buy | Berenberg |
| 3/1/2022 | $30.00 → $22.00 | Market Outperform | JMP Securities |
| 11/9/2021 | $27.00 → $30.00 | Market Outperform | JMP Securities |
SOL-1 is now expected to be enrolled and fully randomized by year-end 2024 Topline clinical data from SOL-1 are now expected in Q4 2025 BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for the SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD). The Company now expects the SOL-1 study to be fully enrolled with all patients randomized by the e
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it has agreed to grant inducement awards to its newly appointed Chief Legal Officer, Todd D.C. Anderman. The awards were made as inducements material to Mr. Anderman's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Mr. Anderman's inducement equity awards were granted effective as of Octo
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in multiple panels and presentations across three ophthalmology meetings in Chicago, Illinois during October 2024. Presentation & Panel Details (all times CT): Eyecelerator® @ AAO 2024: October 17 Panel Title: Fueling Progress: The Power of Innovation and PerseveranceSession: S3Panel Date/Time: Thursday, October 17, 10:00 – 11:00 AMOcular Therapeutix Panelist: P
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
3 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that a late-breaking abstract related to the Phase 1 HELIOS study of AXPAXLI (axitinib intravitreal implant) for non-proliferative diabetic retinopathy (NPDR) was accepted for presentation at the 42nd American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held July 17-20 in Stockholm, Sweden.
Piper Sandler analyst Biren Amin maintains Ocular Therapeutix (NASDAQ:OCUL) with a Overweight and maintains $15 price target.
Shares of Jabil Inc. (NYSE:JBL) fell sharply during Thursday's session following third-quarter results. Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from Benzinga Pro. Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22). Jabil shares dipped 7.8% to $116.37 on Thursday. Here are some other stocks moving in today’s mid-day session. Gainers MGO Global, Inc. (NA
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD
Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata Saroj, OD, to Become Development Strategy Consultant Dr. Waheed's strong industry track record as a CMO and broad expertise in wet AMD and diabetic retinopathy support advancing the Phase 3 AXPAXLI™ program Dr. Kaiser's vast leadership experience in numerous pivotal trials of approved wet AMD products enhances Ocular's transition to a leading retina care company Dr. Gibson and Dr. Saroj bring deep experience in clinical trial execution through their joint involvement in the development and commerc
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)
Scotiabank initiated coverage of Ocular Therapeutix with a rating of Sector Outperform
TD Cowen upgraded Ocular Therapeutix from Hold to Buy and set a new price target of $11.00 from $7.00 previously
Piper Sandler resumed coverage of Ocular Therapeutix with a rating of Overweight and set a new price target of $15.00
SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)
SC 13D/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)
SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)
SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028 Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the se
Clear Regulatory Path for AXPAXLI™ in Wet AMD Through Ongoing SOL-1 and SOL-R Registration-Enabling Trials Ocular to Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8:00 AM ET BEDFORD, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company has received a written response from the U.S. Food and Drug Administration (FDA) that the Phase 3 SOL-R clinical trial is appropriate for use as the
BEDFORD, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the second quarter ended June 30, 2024. Conference Call and Webcast Information:Date: Wednesday, August 7, 2024, at 8:00 AM ETParticipant Dial-In (U.S.): 1 (800) 343-4136Participant Dial-in (International): 1 (203) 518-9843Confer